Prostate Cancer Updates Print
News Releases - Health, Medicine & Nutrition
Written by Zero - the end of prostate cancer   
Monday, 03 June 2013 09:30

FDA Approves New Treatment for Advanced Prostate Cancer

The FDA has approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Patients who are interested in finding out where and when newly FDA approved drug Xofigo will be available can call 1-855-696-3446 (1-855-6Xofigo) or visit www.xofigo.com.

Click Here to Learn More About Xofigo

Agent Orange Linked to Fatal Prostate Cancer

A new study of US Veterans has found that exposure to Agent Orange is linked to a two-fold higher risk of developing the most lethal forms of prostate caner. The researchers suggest a history of exposure to the agent, which contains the dioxin TCDD, a dangerous toxin and carcinogen, should be one of the first things to look for when screening Veterans as it could lead to earlier diagnosis and treatment and prolong survival.

Click Here to Read the Full Article

Man With BRAC2 Gene Has First Preemptive Prostate Removal

Angelina Jolie had her breasts removed after discovering that her genetic makeup gave her an 87 percent chance of breast cancer. Now, an unnamed 53-year-old Londoner has become the first man in the world to have his prostate preemptively removed after discovering that, like the Hollywood actress, his genetic code (carrier of the BRAC 2 gene) made him a prime candidate for prostate cancer.

Although standard tests showed no evidence of cancer, doctors finally agreed to go ahead with the controversial operation—which leaves men infertile as the prostate gland is responsible for the production of semen—and were astounded when, after the operation, examinations showed the organ to be riddled with cancer.

Click Here to Read the Full Article


blog comments powered by Disqus